Table 1.
Overview of literature studies reporting the expression of CYP3A and CYP2C protein or mRNA from patient samples
| Study | References | CYP3A | CYP2C | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | mRNA | Protein | mRNA | ||||||
| Tumor (n) | Healthy (n) | Tumor (n) | Healthy (n) | Tumor (n) | Healthy (n) | Tumor (n) | Healthy (n) | ||
| Breast cancer | |||||||||
| Albin et al. (1993) | [68] | 0% (12) | 0% (12) | – | – | 0% (12) | 0% (12) | – | – |
| Hellmold et al. (1998) | [63] | – | 0%(15) | 75% (4) | 73% (15) | – | 0% (14)c | 100% (4) | 100% (15) |
| Murray et al. (1993) | [66] | 22% (54)a | – | – | – | – | – | – | – |
| Huang et al. (1996) | [62] | – | – | 15% (13) |
73% (11)a 82% (11)b |
– | – | 100% (13) | 100% (11) |
| Yokose et al. (1999) | [67] | 0% (6) | – | – | – | 33% (6) | – | – | – |
| Iscan et al. (2001) | [64] | – | – |
0% (8)a 0% (4)b |
0% (8)a 0% (4)b |
– | – | 83% (6) | 83% (6) |
| Miyoshi et al. (2002) | [101] | 37% (38)a,d | – | – | – | – | – | – | – |
| El-Rayes et al. (2003) | [56] | + (29) | + (29) | – | – | – | – | – | – |
| Kapucuoglu et al. (2003) | [29] | 100% (25)a | 68% (25)a | – | – | – | – | – | – |
| Knüpfer et al. (2004) | [72] | – | – | – | – | – | 100% (10)c | – | |
| Schmidt et al. (2004) | [71] |
100% (11)a 0% (10)b |
– | – | – | – | – | – | |
| Miyoshi et al. (2005) | [102] | 52% (31)a | – | – | – | – | – | – | – |
| Haas et al. (2006) | [70] | 25% (393)a,b | – | – | – | – | – | – | – |
| Vaclavikova et al. (2007) | [65] | – | – | BLQ (40)a | BLQ (40)a | – | – | ||
| Murray et al. (2010) | [32] |
52% (170)a,d,e 19% (170)b,d,e |
– | – | – | 30% (170) | – | – | – |
| Sakurai et al. (2011) | [103] | 55% (42)a | – | – | – | – | – | – | – |
| Floriano-Sanchez et al. (2014) | [69] | + (48)*,a | + (48)a | – | – | – | – | – | – |
| Prostate cancer | |||||||||
| Murray et al. (1995) | [79] | 61% (51) | – | – | – | 25% (51) | – | – | – |
| Yokose et al. (1999) | [67] | 0% (6) | – | – | – | 83% (6) | – | – | – |
| Finnström et al. (2001) | [58] | – | – |
11% (28)a,f 86% (28)b,f |
11% (28)a,f 86% (28)b,f |
– | – | – | – |
| Koch et al. (2002) | [74] | – | – | – |
0% (47)a + (47)b |
– | – | – | – |
| Di Paolo et al. (2005) | [80] | – |
58% (24)a 54% (24)b |
– | – | – | – | – | – |
| Moilanen et al. (2007) | [77] | – | 100% (6)b | – | – | – | – | – | – |
| Bièche et al. (2007) | [54] | – | – | – | + (32)b | ||||
| Leskelä et al. (2007) | [76] | 0% (35)b | 100% (10)b | 0% (10)b | + (10)b | – | – | – | – |
| Fujimura et al. (2009) | [81] | 75% (107)a | 93% (88)a | – | – | – | – | – | – |
| Mitsiades et al. (2012) | [75] | – | – | + (146)a,b | + (29)**,a,b | – | – | – | – |
| NSCLC | |||||||||
| Nakajima et al. (1994) | [85] | – | – | – | – | + (27) | + (11) | – | – |
| Kivistö et al. (1995) | [86] | 25% (32) | 34% (32) | – | – | – | – | – | – |
| Kivistö et al. (1996) | [87] | 100% (8) | 100% (8) |
0% (8)a 50% (8)b |
0% (8)a 100% (8)b |
– | – | – | – |
| Anttila et al. (1997) | [88] | – | 18,5% (27)a | – |
13% (8)a 100% (8)b |
– | – | – | – |
| Macé et al. (1998) | [84] | – | – | – |
0% (14)a 93% (14)b |
– | – | – | 100% (14) |
| Yokose et al. (1999) | [67] | 0% (18) | 0% (18) | ||||||
| Fujitaka et al. (2001) | [90] | – | – | + (10)a | + (10)a | – | – | + (10)* | + (10) |
| Bièche et al. (2007) | [54] | – | – | – | + (6)b | – | – | – | – |
| Qixing et al. (2017) | [89] |
74% (87)***,a,d + (87)b,d |
+ (87)a + (87)***,b |
– | – | – | – | – | – |
| Endometrial cancer | |||||||||
| Hukkanen et al. (1998) | [94] | – | – | – |
57% (7)a 43% (7)b |
– | – | – | – |
| Yokose et al. (1999) | [67] | 0% (12) | 0% (12) | ||||||
| Sarkar et al. (2003) | [95] | – | – | – | 57% (23)a | – | – | – | – |
| Masuyama et al. (2003) | [50] | – | – | + (20)a | – | – | – | – | – |
| Ovarian cancer | |||||||||
| Yokose et al. (1999) | [67] | 0% (12) | – | – | – | 0% (12) | – | – | – |
| Klose et al. (1999) | [91] | – | – | – | – | – | – | – | 100% (1) |
| Downie et al. (2005) | [98] |
91% (99)/ 80% (22)a,g 66% (99)/ 55% (22)b,g |
64% (13)a 55% (13)b |
– | – |
17% (99)/ 10% (22)g |
36% (13) | – | – |
| Bièche et al. (2007) | [54] | – | – | – | + (15)b | – | – | – | + (15) |
| DeLoia et al. (2008) | [97] | – | – |
9% (47)a 89% (47)b |
– | – | – | 69% (48)c | – |
The percentages shown indicate the number of samples in which CYP enzymes could be detected, with in parentheses the total amount of samples/patients analyzed. (+) indicates CYP enzymes were expressed, but the exact number of positive samples was not described or presented as immunoreactivity score. (−) indicates not measured. P values indicate higher proportion, immunoreactivity score, or expression level compared to respective tumor/non-tumor sample, *P < 0.05, **P < 0.01, ***P < 0.001
BLQ below limit of quantification
aOnly CYP3A4
bOnly CYP3A5
cOnly CYP2C8
dPercentage indicates a fraction of tumors with moderate/high expression
eOriginal data from publication received from the authors
fNo distinction between tumor and non-tumor tissue
gPercentages for primary ovarian cancer and peritoneal metastases, respectively